DCZ0415 |
Catalog No.GC39370 |
강력한 TRIP13 억제제인 DCZ0415는 비상동 말단 연결 복구를 손상시키고 NF-κB 활성을 억제합니다. DCZ0415는 시험관 내, 생체 내 및 약물 내성 골수종 환자에서 유래한 1차 세포에서 항골수종 활성을 유도합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2242470-43-3
Sample solution is provided at 25 µL, 10mM.
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].
[1]. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *